AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06002490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101
Description: The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms.
Study NCT06002490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Description: Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
Study NCT06002490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
Study NCT06677567 — intervention group
Intervention type: OTHER
Intervention: Air-Q Intubating Airway
Description: Patients will be inserted Air-Q Intubating Airway under general anesthesia
Study NCT06677567 — intervention group
Intervention type: OTHER
Intervention: proseal laryngeal mask
Description: Patients will be inserted proseal laryngeal mask under general anesthesia.
Study NCT06676709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMMUNEPOTENT-CRP (I-CRP)
Description: IMMUNEPOTENT-CRP (I-CRP), a bovine dialyzable leukocyte extract (DLE) obtained from disrupted spleen cells, is a mixture of low-molecular-weight peptides (\<12 kDa) that exhibit non-specific immunomodulatory properties.
Study NCT06676709 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The placebo was prepared from a lyophilized corn starch extract and was provided in an identical appearance and presentation to IMMUNEPOTENT-CRP (I-CRP).
Study NCT06678698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Panel Effective Photobiomodulation Therapy
Description: Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals.~This group will receive photobiomodulation from a whole-body panel of low intensity LEDs
Study NCT06678698 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Panel Photobiomodulation Therapy
Description: Use of common red lamp to perform the sham photobiomodulation for the panel group
Study NCT06678698 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Modified ILIB Sham Photobiomodulation Therapy
Description: ILIB Therapy device turned off for the sham ILIB therapy
Study NCT06678698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified ILIB Photobiomodulation Therapy
Description: Common laser used in ILIB mode for modified ILIB therapy
Study NCT06679998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose, AAPB by injection, intravenous drip.
Description: Subjects received a single intravenous infusion of AAPB for injection. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, and each time was continuously injected for 60 min±5min.
Study NCT06679998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Single dose, placebo, intravenous drip.
Description: Subjects received a single intravenous infusion of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time.
Study NCT06679998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dosing, AAPB for injection, intravenous drip
Description: Subjects received AAPB for injection with multiple intravenous drips. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, 60 min±5min each time, for 7 consecutive days.
Study NCT06679998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multiple dosing, placebo, IV drip
Description: Subjects received multiple intravenous doses of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time for 7 consecutive days.
Study NCT06680336 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mulit-componant neuropsychological assessment
Description: Multi-component cognitive assessment including following domains: attention \& information speed, executive functioning, verbal memory, language, visuospatial-construction and orientation.
Study NCT06680336 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multimodal MRI
Description: Structural MRI (e.g., MPRAGE, DTI) and functional MRI (introducing a modified working memory task for stroke patients)
Study NCT06681675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The group that applied the Intrapartum Care Model
Description: In pregnant women with cervical dilatation of 5 cm, the Personal Information Form was completed at the initial clinic admission.~•The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations.~Data were collected using the Personal Information Form, Labor and Postpartum Follow-up Form, Visual Analog Scale (VAS), Labor Comfort Scale (CSC), Intrapartum Fear of Labor Scale, and Women's Perception of Supportive Care Given During Labor Scale. VAS, CSC, and Fear of Labor Scale were applied to women when cervical dilation was 5 cm and 9 cm. After delivery, the Women's Perception of Supportive Care Given During Labor Scale was applied.
Study NCT06681181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4528287
Description: GSK4528287 will be administered.
Study NCT06681181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT06680258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1120
Description: TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα)
Study NCT06680258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is an IV administered biologic.
Study NCT06680258 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is an IV administered biologic.
Study NCT06680258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is an IV administered biologic.
Study NCT06680258 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is an IV administered biologic.
Study NCT06681701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Manual Therapy and Pulmonary Exercises
Description: Diaphragmatic breathing exercise:~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia.~Rib mobilization from sitting:~Rib mobilization from supine:~Central Posterior-Anterior (PA) mobilization of thoracic facet joints:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:
Study NCT06681701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Manual Therapy and Pulmonary Exercises
Description: Diaphragmatic breathing exercise:~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia.~Rib mobilization from sitting:~Rib mobilization from supine:~Central Posterior-Anterior (PA) mobilization of thoracic facet joints:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:
Study NCT06703697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eDrugSafe
Description: The eDrugSafe mobile web platform enables management of medication history and provides electronic access to medicinal product information (ePI). QR codes are separately provided for prescription records to facilitate direct access to ePI.
Study NCT05292287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polar Ignite Wearable Activity Monitor
Description: A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
Study NCT06710587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voy Program
Description: Voy Program - coaching and access to the Voy app to support behavioural changes
Study NCT06708676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation
Description: Washed microbiota suspension delivered through mild-gut and lower-gut
Study NCT06710327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (IV)
Description: The intervention is administered as a clear, colorless solution infusion. The dosage administered is a 1 gram intravenous (IV) push, delivered immediately before starting the Aquablation therapy. The administration of TXA occurs only once, as a single dose preoperatively.
Study NCT06710327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive a saline solution, which is a sodium chloride (0.9%) IV infusion, identical in appearance to the TXA solution. The saline is administered as a single 1 gram-equivalent volume intravenous (IV) push, delivered immediately before the Aquablation therapy commences. This singular administration matches the frequency and timing of the TXA intervention to ensure uniformity across both study groups, maintaining the blinding of the study.
Study NCT06707857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tendon neuroplastic training
Description: Throughout the training, participants pain, range of motion and disability were monitored and they were asked to report any discomfort or unusual sign.
Study NCT06707857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional training
Description: Throughout the training, participants pain, range of motion and disability were monitored and they were asked to report any discomfort or unusual sign.
Study NCT06708637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYB203 2 mg (0.05 mL of 40 mg/mL)
Description: IVT administration of FYB203 in a PFS
Study NCT06300762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superabsorbent dressing application
Description: Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate
Study NCT06300762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Superabsorbent dressing application
Description: Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate
Study NCT06709755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Teen Problem Solving
Description: STePS is a group-based, teen-focused intervention aimed at reducing diabetes-specific emotional distress and building diabetes resilience. STePS is grounded in both cognitive-behavioral and social problem-solving theories, which recognize the interrelationships among difficult situations, beliefs related to the cause and consequences of those situations, and the emotional and behavioral consequences of those beliefs, and which addresses problem solving strategies that influences ones' adaptive functioning in real-life social settings, distinguishing between problem solving and solution implementation. STePS reduces distress by teaching: 1) emotion regulation, helping teens learn to link beliefs, emotions, and behaviors; to challenge negative thinking by evaluating the accuracy of one's beliefs; and learning new coping skills.2) perspective taking, helping teens learn to identify their own thinking style.
Study NCT06709755 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Arm Description: The Participants will receive diabetes education directed toward adolescents matching time, group experience and homework assignments, delivered virtually
Study NCT06708195 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Group experimental
Description: Type: Inactive TENS (placebo) Frequency: 1 session Session duration: 15 minutes Application area: Skin over the bilateral parotid glan
Study NCT06708195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group experimental
Description: Type: Inactive TENS (placebo) Frequency: 1 session Session duration: 15 minutes Application area: Skin over the bilateral parotid glan
Study NCT06710314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colorectal cancer patients with hypertension
Description: Colorectal cancer patients with hypertension
Study NCT06710314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colorectal cancer patients with diabetes
Description: Colorectal cancer patients with diabetes
Study NCT06710314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colorectal cancer patients with fatty liver
Description: Colorectal cancer patients with fatty liver
Study NCT06708403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Judo-Specific Injury Prevention Exercise Program
Description: The intervention includes a structured program designed specifically for judo athletes to prevent injuries and enhance performance. The program consists of warm-up exercises, strength and conditioning drills, balance improvement exercises, agility training, and sport-specific movements. It is delivered over six weeks, with participants completing three sessions per week. Each session is progressively tailored to improve overall motor skills, prevent overuse injuries, and enhance judo-specific abilities.
Study NCT06706791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: participants will be divided in two groups one group will empagliflozin 10mg once daily along with standard treatment secong group receiving placebo once daily along with standard treatment.
Study NCT06706791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: participants will be divided in two groups one group will empagliflozin 10mg once daily along with standard treatment secong group receiving placebo once daily along with standard treatment.
Study NCT06709170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel asymmetrical linear stapler
Description: Novel asymmetrical linear stapler
Study NCT06709170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Signia™
Description: Signia™
Study NCT06709794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational flyer
Description: In addition to a standard eligibility notice informing participants of their eligibility for marketplace coverage, they receive an informational flyer describing what Covered California is, the availability of financial assistance, and information on benefit design and private insurance terminology, such as deductibles and copays
Study NCT06709794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified eligibility notice with plan information
Description: a modified eligibility notice that includes information on the pre-selected lowest-cost silver health insurance plan with a personalized quote for their net premium amount in addition to the informational flyer and instead of a standard eligibility notice
Study NCT05629546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced memory-like natural killer cells
Description: Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).
Study NCT04877015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Vibrotactile Coordinated Reset (vCR)
Description: Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
Study NCT04877015 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Vibrotactile Coordinated Reset (vCR)
Description: Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
Study NCT05629546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatilmab
Description: Standard of care
Study NCT05629546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Standard of care
Study NCT05796193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alpha-cypermethrin and PBO LLIN
Description: Veeralin Long lasting insecticidal net with Alpha-cypermethrin Pyrethroid insecticide and PBO
Study NCT05796193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alpha-cypermethrin and Clorfenapyr LLIN
Description: Interceptor G2 dual active ingredient LLIN with with Alpha-cypermethrin Pyrethroid insecticide and Clorfenapyr
Study NCT05796193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-cypermethrin only LLIN
Description: reference: standard pyrethroid LLIN
Study NCT04893811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trumenba
Description: Bivalent recombinant lipoprotein 2086 vaccine
Study NCT06369155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azenosertib
Description: Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.
Study NCT05526157 — intervention group
Intervention type: DRUG
Intervention: Finerenone (Kerendia, BAY 948862)
Description: Retrospective analysis using secondary data collection from various sources
Study NCT05526157 — intervention group
Intervention type: DRUG
Intervention: Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Description: Retrospective analysis using secondary data collection from various sources
Study NCT06614283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes self management @ click
Description: A mobile application tailored for patients with Type 2 diabetes, aiming to enhance their self-management practices will be used for the intervention arm. The app includes features such as medication tracking, appointment scheduling, patient data storage, advice for treatment and follow-ups, health education and promotion, and real-time health monitoring.
Study NCT06615297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonographic evaluation
Description: facial nerve thickness (right/left), depressor labi inferior, depressor anguli oris, buccinator and risorius muscles will be evaluated.
Study NCT06615089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance training
Description: the elderly patients will receive balance training in the form of proprioceptive and vestibular training components. proprioceptive training include Standing static balance, lateral weight transfer, Lateral weight transfer near to chair, tandem closed eyes, walking on toes, Postural control using ball. Vestibular training in the form of Balance with head movement, seated lateral step in addition to Insoles inside the subjects' own regular shoes
Study NCT06615089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthotic prescription
Description: the elderly patients will receive Insoles inside the subjects' own regular shoes
Study NCT06615089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: orthotic prescription
Description: the elderly patients will receive Insoles inside the subjects' own regular shoes
Study NCT06615362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preparation of dentin membrane from hopeless tooth for Guided Bone Regeneration in Immediate Implant
Description: tooth extraction , preparation of dentin membrane ,immediate implantation ,Xenogeneic bone graft material, application of dentin derived barrier membrane
Study NCT06615362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen Membrane for Guided Bone Regeneration in Immediate Implant
Description: like group one but with application of collagen membrane
Study NCT06169852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unilateral dual-target (STN/GPi) DBS
Description: Participants will be randomly assigned either DBS stimulation in the STN alone, GPi alone, or a combination of stimulation in the STN and GPi.